It is generally accepted that Epstein ± Barr virus (EBV) latent genes EBNA-2, EBNA-3A, -3C, EBNA-LP and LMP1 are essential for growth transformation and immortalization of B lymphocytes. Among these genes, LMP1 plays a key role in the survival and dissemination of the infected B cells by inducing anti-apoptotic genes and surface expression of several activation antigens and adhesion molecules. We have previously shown that antisense oligodeoxynucleotides directed to LMP1 mRNA, eectively suppress LMP1 gene expression and substantially reduce B95.8 cell proliferation. In this study, we have used antisense LMP1 oligomers to investigate whether LMP1 suppression might in¯uence the expression of latent EBV genes with oncogenic potential, anti-apoptotic genes, or aect the phenotype of EBV-infected B95.8 cells. Our data show that LMP1 suppression does not aect the transcription of EBNA-2, EBNA-3A, -3B and -3C genes, or that of bcl-2 and mcl-1 anti-apoptotic genes. In contrast, consistent modi®ca-tions in the expression of CD39, CD54, CD23, CD11 and CD10 molecules were observed in B95.8 cells after treatment with antisense LMP1. Our ®ndings support the possibility for using LMP1 antisense oligomers as therapeutics in EBV-associated tumors.
It is generally accepted that Epstein ± Barr virus (EBV) latent genes EBNA-2, EBNA-3A, -3C, EBNA-LP and LMP1 are essential for growth transformation and immortalization of B lymphocytes. Among these genes, LMP1 plays a key role in the survival and dissemination of the infected B cells by inducing anti-apoptotic genes and surface expression of several activation antigens and adhesion molecules. We have previously shown that antisense oligodeoxynucleotides directed to LMP1 mRNA, eectively suppress LMP1 gene expression and substantially reduce B95.8 cell proliferation. In this study, we have used antisense LMP1 oligomers to investigate whether LMP1 suppression might in¯uence the expression of latent EBV genes with oncogenic potential, anti-apoptotic genes, or aect the phenotype of EBV-infected B95.8 cells. Our data show that LMP1 suppression does not aect the transcription of EBNA-2, EBNA-3A, -3B and -3C genes, or that of bcl-2 and mcl-1 anti-apoptotic genes. In contrast, consistent modi®ca-tions in the expression of CD39, CD54, CD23, CD11 and CD10 molecules were observed in B95.8 cells after treatment with antisense LMP1. Our ®ndings support the possibility for using LMP1 antisense oligomers as therapeutics in EBV-associated tumors. Oncogene (2002 Oncogene ( ) 21, 4166 ± 4170. doi:10.1038 Keywords: EBV; LMP1; antisense oligodeoxynucleotides; EBV transforming genes; anti-apoptotic genes; B cell phenotype Epstein Barr virus (EBV) is the causative agent of infectious mononucleosis and it is also associated with a variety of human malignancies that include Burkitt's lymphoma (BL), nasopharyngeal carcinoma, Hodgkin's disease, and lymphoproliferative disorders in immunode®cient individuals (Miller, 1990) . In vitro, EBV is able to transform and immortalize resting B lymphocytes leading to the outgrowth of permanently proliferating lymphoblastoid cell lines (LCLs). In these cells, EBV expression is restricted to a limited number of latent genes that include six nuclear antigens (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA-LP), three integral membrane proteins (LMP1, LMP2A and LMP2B) and two small nuclear RNAs (Farrell, 1995) . Experiments with recombinant viruses have demonstrated that LMP1, EBNA-2, EBNA-3A, EBNA-3C and EBNA-LP genes are essential for primary B cells transformation. Among these genes, LMP1 is a key eector of B cell immortalization (Kaye et al., 1993; Cohen et al., 1989; Hammerschmidt and Sugden, 1989; Kempkes et al., 1995 , Tomkinson et al., 1993 . It is a classical oncogene, as shown by its ability to transform rodent ®broblast cell lines (Baichwal and Sugden, 1988; Wang et al., 1985) and human epithelial cells (Fahraeus et al., 1990; Hu et al., 1993; Nicholson et al., 1997) , rendering them tumorigenic. In vivo, LMP1 expression induces B cell lymphoma in transgenic mice (Kulwichit et al., 1998) . Transfection experiments of LMP1 gene into EBV-negative BL cell lines have shown that LMP1 expression causes up-regulation of the anti-apoptotic genes, bcl-2 and mcl-1 with the latter rapidly and transiently inducible before bcl-2 stimulation (Henderson et al., 1991; Rowe et al., 1994; Wang et al., 1996) . In addition, in a similar cell system, the b¯-1 gene, a homologue of bcl-2, has been reported to be transcriptionally up-regulated by LMP1 expression (D'Souza et al., 2000) .
EBV-infected B lymphocytes express a number of B cell activation markers and cellular adhesion molecules characteristic of antigen or mitogen-activated B lymphocytes (Kintner and Sudgen, 1981; Patarroyo et al., 1986; Thorley-Lawson et al., 1985) .
Studies carried out by transfecting the LMP1 gene into a number of EBV negative B lymphoma cell lines have elucidated the contribution of this gene to the Oncogene (2002) 21, 4166 ± 4170 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc transformed B cell phenotype. LMP1 expression in all cell lines tested promptly up-regulates cellular adhesion molecules ICAM1 (CD54), LFA1 (CD11) and LFA3 (CD58), while diminishing the expression of CD10, the common acute lymphoblastic leukemia antigen (CALLA). In addition, depending on the cellular context, LMP1 induces speci®c B cell activation antigens such as CD39, CD23, CD21, CD40 and CD44 (Wang et al., 1988 (Wang et al., , 1990 .
Because LMP1 plays a central role in the overall EBV strategy to suppress the cellular apoptotic program, we developed LMP1 antisense oligonucleotides that in EBV-infected B95.8 cells caused a substantial loss of LMP1 mRNA, a signi®cant decrease of LMP1 protein and a 50% inhibition of cell proliferation (Mattia et al., 1997) .
This study set out to investigate whether in B95.8 cells, LMP1 down-regulation by antisense molecules might modulate the expression of other EBV latent genes essential for B cell immortalization and/or decrease the expression of bcl-2 and mcl-1 antiapoptotic genes.
In addition, the expression of B cell activation antigens and adhesion molecules known to be induced by LMP1, was analysed by¯ow cytometry after treating B95.8 cells with LMP1 antisense oligonucleotides.
In order to evaluate whether suppression of the LMP1 gene by antisense DNA might aect the expression of other EBV immortalizing genes, B95.8 cells were incubated with either the LMP1 antisense oligomer AS2 or with the control Sc2 oligonucleotide, a randomly scrambled version of the AS2 sequence (Mattia et al., 1997) . Total RNA was isolated from untreated and oligonucleotide-treated cells and RT ± PCR experiments were performed for EBNA-2, EBNA-3A and EBNA-3C genes; in addition, RT ± PCR was carried out for EBNA-3B, as an EBV latent gene that lacks oncogenic potential, and for LMP1, to verify the ecacy of the antisense treatment. Figure 1A shows that, following the incubation of B95.8 cells with antisense AS2, LMP1 mRNA was virtually undetectable by RT ± PCR, while comparable levels of the 381 bp ampli®cation product were measured in untreated cells and in cells treated with the Sc2 oligomer. The results of the RT ± PCR experiments carried out on the same RNA samples, with primers speci®c for EBNA-2, EBNA-3A, EBNA-3B and EBNA-3C genes are shown in Figure 1B . It is evident for all the genes tested that no signi®cant variations occurred in the intensity of the signals corresponding to the speci®c ampli®cation products (249, 276, 125 and 153 bp, respectively), independent of LMP1 oligomers added to B95.8 cultures. These results indicate that down-regulation of the LMP1 gene does not aect the transcription levels of the latent EBV genes tested, irrespective of their immortalization properties.
We next investigated whether suppression of LMP1 gene transcriptional expression might in¯uence the transcription of two LMP1-induced cellular antiapoptotic genes, bcl-2 and mcl-1. The results of RT ± PCR experiments carried out for bcl-2 and mcl-1 genes are shown in Figure 2 . Again, suppression of LMP1 Figure 1 Analysis of EBV transcripts by RT ± PCR in B95.8 cells untreated and treated with LMP1 oligomers. B95.8 cells, cultured to mid-log phase in RPMI medium supplemented with antibiotics and 2% (v/v) Biogro1 concentrated supplement (Biological Industries), were diluted in the same medium to 2.5610 5 /ml and seeded in 1.6 ml/well in 6-well plates. At 0, 24 and 48 h LMP1 antisense (AS2) and LMP1 non-sense (Sc2) oligodeoxynucleotides were added to a ®nal concentration of 20 mM (Mattia et al., 1997) . After 54 h of incubation untreated (C) and oligomers-treated cells were harvested and total RNA puri®ed by RNeasy mini kit columns (Qiagen). RNA derived from about 120 000 cells was reverse transcribed in 20 ml volume, in the presence of 2.5 mM poly dT tailed primer, 5 mM MgCl 2 , 1 mM dNTPs 50 U MuLV-RT, 16RT ± PCR buer (10 mM Tris pH 8.3, 50 mM KCl). PCR assays were carried out on 10 ml of the reverse transcription product by using the primers shown in Table  1 . Products of the dierent ampli®cation reactions were resolved by electrophoresis on a 1.5% agarose gel and stained by ethidium bromide. The signals corresponding to gapdh gene, quanti®ed by densitometry, were used to normalize the amount of total RNA in each sample Figure 2 Analysis of bcl-2 and mcl-1 transcripts by RT ± PCR in B95.8 cells untreated or treated with LMP1 oligomers. B95.8 cells were incubated and treated as described for Figure 1 . C, untreated cells; AS2, cells treated with LMP1 antisense oligomer; Sc2, cells treated with LMP1 scrambled sequence expression by antisense AS2 treatment of B95.8 cells did not alter transcription levels of either of the two anti-apoptotic genes, as the intensity of the bands corresponding to their ampli®cation products (318 and 580 bp, respectively) was substantially similar in untreated or in AS2 or Sc2 treated cells.
Because it has been reported that suppression of LMP1 by atisense oligodeoxynucleotides induces a substantial reduction of Mcl-1 and Bcl-2 proteins in EBV-immortalized lymphoblastoid cells (Kenney et al., 1998 , Noguchi et al., 2001 , we examined the levels of mcl-1 and bcl-2 transcripts in two human-derived EBVpositive cell lines, treated with LMP1 oligomers as previously described.
Incubation of EA (EBV-transformed B cells) or RPMI 6666 (Hodgkin's lymphoma-derived cells) with antisense AS2 caused a decrease of cell proliferation by 60 and 30%, respectively (data not shown). The results of RT ± PCR experiments, carried out with the primers speci®c for mcl-1 and bcl-2 are shown in Figure 3 .
Treatment with LMP1 antisense oligodeoxynucleotides substantially decreased the levels of LMP1 transcripts in both EA and RPMI 6666 cells as compared to those measured in either untreated or Sc2-treated cells. In contrast, no signi®cant variations could be detected in the signals corresponding to mcl-1 and bcl-2 ampli®cation products independent of exposure of EA or RPMI 6666 cells to LMP1 oligomers.
In addition, evaluation of the EBNA transcripts by RT ± PCR in EA and RPMI 6666 cells, did not reveal any signi®cant dierence in the levels detected in AS2-treated as compared to Sc2-treated or untreated cells, again con®rming the results obtained with B95.8 cells (data not shown).
We therefore undertook a series of experiments to assess whether in AS2-treated B95.8 cells, downregulation of LMP1 gene expression might induce modi®cations in the expression of cell surface antigens and adhesion molecules characteristic of transformed B cells. To this end, cell surface immuno¯uorescence was performed on live cells, either untreated or treated with LMP1 oligonucleotides, using saturating amounts of labeled monoclonal antibodies against CD10, CD11, CD23, CD39 and CD54. In dierent experiments, untreated B95.8 cells expressed CD39 and CD10 antigens on 35 ± 60% and on 40 ± 70% of the cell population, respectively, while a lower percentage of cells (between 5 ± 10%) was positive for CD23, CD54 and CD11. As illustrated in Figure 4 , LMP1 suppression by antisense oligonucleotides consistently altered the percentage of cells positive for the dierent antigens. A major dierence was noted with activation marker CD39, the expression of which dropped sharply (by 90%) in the cells subjected to treatment with antisense LMP1, as compared to untreated cells. Similarly, CD54 and CD11 antigens decreased by 60 and 40%, respectively. In contrast, the percentage of cells positive for CD23 antigen increased about twofold in AS2 treated cultures with respect to values measured in untreated cells, while under the same conditions, a moderate induction was observed for CD10 antigen. The variations in the expression of cellular markers measured in AS2-treated cultures appeared to be speci®c. Incubation of B95.8 cells with Sc2 oligonucleotides for the same length of time, did not aect the pattern of antigen expression which remained substantially similar to that of untreated B95.8 cells (data not shown). Ecient transformation of B cells requires the cooperative eect of all latent EBV genes with immortalization properties. In particular, EBNA-2 gene expression is required to transactivate LMP1 as well as EBNA-1, EBNA-3A, -3B and -3C genes. Our data, demonstrating that suppression of LMP1 does not in¯uence the transcriptional expression of EBNA-2, EBNA-3A, -3B and -3C genes, indicate that LMP1 gene does not exert regulatory functions on any of the latent genes tested.
We show here that in three EBV-positive cell lines, two lymphoblastoid and a Hodgkin's lymphomaderived line, downregulation of LMP1 expression by LMP1-directed antisense oligodeoxynucleotides does not aect the levels of transcription of the two antiapoptotic genes mcl-1 and bcl-2.
Several studies carried out to investigate the correlation between LMP1 expression and Bcl-2 protein levels, have shown that induction of Bcl-2 by LMP1 is a delayed response restricted to target cells of the B cell lineage (Martin et al., 1993 , Rowe et al., 1994 , Wang et al., 1996 . Kenney et al. (1998) and more recently Noguchi et al. (2001) have demonstrated in these cells that a decrease of Bcl-2 and Mcl-1 protein levels occurs after treating EBV-immortalized lymphoblastoid cell lines with LMP1 antisense oligos.
In the light of these ®ndings, our results strongly suggest that the control of LMP1 on bcl-2 expression in EBV-infected B cells, is exerted at a posttranscriptional level and/or that other LMP1-regulated cellular factors could, in turn, modulate Bcl-2 protein content. The data recently reported (D'Souza et al., 2000) showing that in LMP1-transfected EBV-negative Burkitt's lymphoma cells, an increase in the level of Bcl-2 protein was detected earlier than that of the corresponding mRNA, are in agreement with the hypothesis that translational mechanisms are also involved in the regulation of bcl-2 expression by LMP1.
LMP1 gene expression directly contributes to determine the phenotype of EBV-transformed B cells. We report here that LMP1 down-regulation induces phenotypic eects on EBV-infected B cells. The decrease of the activation molecule CD39, and that of adhesion molecules ICAM1 (CD54) and LFA1 (CD11), following antisense-induced LMP1 decrease, is consistent with the data reporting the stimulation of these antigens after transfection of the LMP1 gene into EBV-negative B cell lines. Moreover, the expression of CD10 antigen in AS2-treated cells appears also modulated by LMP1 expression since down-regulation of this gene was observed in a number of cell lines after transfection with LMP1 (Wang et al., 1990) . LMP1 downregulation, surprisingly, increases CD23 expression in B95.8 cells. Since LMP1 and EBNA-2 genes (Wang et al., 1990 ) cooperatively induce CD23, a possible explanation for this result might be found in a compensatory mechanism of CD23 superinduction played by EBNA-2 in the absence of LMP1.
The LMP1 gene has pleiotropic eects on cellular phenotype in vitro and in vivo, consistent with its playing a key role in the initiation or maintenance of EBV-induced tumor (Baichwal and Sugden, 1988; Wang et al., 1985; Fahraeus et al., 1990; Hu et al., 1993; Nicholson et al., 1997; Kulwichit et al., 1998) .
Our results indicate that treatment of B95.8 cells with antisense oligodeoxynucleotides targeted to LMP1 eectively modulates the expression of LMP1-related cell surface markers and activation molecules associated with the phenotype of EBV-transformed B cell (Kintner and Sudgen, 1981; Patarroyo et al., 1986; Thorley-Lawson et al., 1985) . Since the phenotypic characteristics of EBV-infected B cells play an important role in the behavior of EBV-based lymphomas, and because LMP1 is expressed in the majority of the EBV associated tumors, our ®ndings suggest the potential use of LMP1 antisense oligonucleotides as therapeutic agents. 
